|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
2
|
Singh MP, Cho HJ, Kim JT, Baek KE, Lee HG
and Kang SC: Morin Hydrate Reverses Cisplatin Resistance by
Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular
Carcinoma. Cancers (Basel). 11:9862019. View Article : Google Scholar
|
|
3
|
Stone NJ, Robinson JG, Lichtenstein AH,
Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D,
Lloyd-Jones DM, et al American College of Cardiology/American Heart
Association Task Force on Practice Guidelines, : 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: A report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 63:2889–B2934.
2014. View Article : Google Scholar
|
|
4
|
Amarenco P, Bogousslavsky J, Callahan A
III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic
L, Szarek M, Welch KM, et al Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) Investigators, : High-dose
atorvastatin after stroke or transient ischemic attack. N Engl J
Med. 355:549–559. 2006. View Article : Google Scholar
|
|
5
|
Zhang L, Lv H, Zhang Q, Wang D, Kang X,
Zhang G and Li X: Association of SLCO1B1 and ABCB1 Genetic Variants
with Atorvastatin-induced Myopathy in Patients with Acute Ischemic
Stroke. Curr Pharm Des. 25:1663–1670. 2019. View Article : Google Scholar
|
|
6
|
Wu J, Wong WW, Khosravi F, Minden MD and
Penn LZ: Blocking the Raf/MEK/ERK pathway sensitizes acute
myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer
Res. 64:6461–6468. 2004. View Article : Google Scholar
|
|
7
|
Sun HY and Singh N: Antimicrobial and
immunomodulatory attributes of statins: Relevance in solid-organ
transplant recipients. Clin Infect Dis. 48:745–755. 2009.
View Article : Google Scholar
|
|
8
|
Osmak M: Statins and cancer: Current and
future prospects. Cancer Lett. 324:1–12. 2012. View Article : Google Scholar
|
|
9
|
Kong Y, Cao XN, Zhang XH, Shi MM, Lai YY,
Wang Y, Xu LP, Chang YJ and Huang XJ: Atorvastatin enhances bone
marrow endothelial cell function in corticosteroid-resistant immune
thrombocytopenia patients. Blood. 131:1219–1233. 2018. View Article : Google Scholar
|
|
10
|
Green DR: Apoptotic pathways: Paper wraps
stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar
|
|
11
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.
|
|
12
|
Nuñez G, Benedict MA, Hu Y and Inohara N:
Caspases: The proteases of the apoptotic pathway. Oncogene.
17:3237–3245. 1998. View Article : Google Scholar
|
|
13
|
Wang J, Li H, Xia C, Yang X, Dai B, Tao K
and Dou K: Downregulation of CENPK suppresses hepatocellular
carcinoma malignant progression through regulating YAP1.
OncoTargets Ther. 12:869–882. 2019. View Article : Google Scholar
|
|
14
|
Chen M, Wu L, Tu J, Zhao Z, Fan X, Mao J,
Weng Q, Wu X, Huang L, Xu M, et al: miR-590-5p suppresses
hepatocellular carcinoma chemoresistance by targeting YAP1
expression. EBioMedicine. 35:142–154. 2018. View Article : Google Scholar
|
|
15
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Biol.
17:2054–2060. 2007. View Article : Google Scholar
|
|
16
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar
|
|
17
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar
|
|
18
|
Janse van Rensburg HJ, Azad T, Ling M, Hao
Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ and
Yang X: The Hippo Pathway Component TAZ Promotes Immune Evasion in
Human Cancer through PD-L1. Cancer Res. 78:1457–1470. 2018.
View Article : Google Scholar
|
|
19
|
Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong
J, Sun X and Li J: Verteporfin suppresses cell survival,
angiogenesis and vasculogenic mimicry of pancreatic ductal
adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci.
108:478–487. 2017. View Article : Google Scholar
|
|
20
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar
|
|
21
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar
|
|
22
|
Keren-Paz A, Emmanuel R and Samuels Y: YAP
and the drug resistance highway. Nat Genet. 47:193–194. 2015.
View Article : Google Scholar
|
|
23
|
Coggins GE, Farrel A, Rathi KS, Hayes CM,
Scolaro L, Rokita JL and Maris JM: YAP1 Mediates Resistance to
MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS
Signaling. Cancer Res. 79:6204–6214. 2019. View Article : Google Scholar
|
|
24
|
Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin
J, Han G, Scott AW, Dong X, Huo L, et al: YAP1-Mediated CDK6
Activation Confers Radiation Resistance in Esophageal Cancer -
Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in
Esophageal Cancer. Clin Cancer Res. 25:2264–2277. 2019. View Article : Google Scholar
|
|
25
|
Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS,
Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, et al: Significant
association of oncogene YAP1 with poor prognosis and cetuximab
resistance in colorectal cancer patients. Clin Cancer Res.
21:357–364. 2015. View Article : Google Scholar
|
|
26
|
Vazquez-Marin J, Gutierrez-Triana JA,
Almuedo-Castillo M, Buono L, Gomez-Skarmeta JL and Mateo JL:
Wittbrodt JandMartinez-Morales JR: yap1b, a divergent Yap/Taz
family member, cooperates with yap1 in survival and morphogenesis
via common transcriptional targets. Development. 146:dev1732862019.
View Article : Google Scholar
|
|
27
|
Song Y, Sun Y, Lei Y, Yang K and Tang R:
YAP1 promotes multidrug resistance of small cell lung cancer by
CD74-related signaling pathways. Cancer Med. 9:259–268. 2020.
View Article : Google Scholar
|
|
28
|
Shi J, Li F, Yao X, Mou T, Xu Z, Han Z,
Chen S, Li W, Yu J, Qi X, et al: The HER4-YAP1 axis promotes
trastuzumab resistance in HER2-positive gastric cancer by inducing
epithelial and mesenchymal transition. Oncogene. 37:3022–3038.
2018. View Article : Google Scholar
|
|
29
|
Errico A: Targeted therapies: Hippo
effector YAP1 inhibition - towards a new therapeutic option to
overcome drug resistance. Nat Rev Clin Oncol. 12:1902015.
View Article : Google Scholar
|
